clinical trial · NCT05110846
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Carmot Therapeutics, Inc.·phase2·completed·n = 103
ObesityOverweightType 2 Diabetes MellitusPlaceboCT-868
brief summary
A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).
started
Feb 22, 2022
primary completion
Feb 28, 2023
completion
Feb 28, 2023
last updated
Feb 5, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Center Study to Evaluate the Efficacy, Safety, and Tolerability of CT-868 Administered for 26 Weeks to Overweight and Obese Participants With Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol